Sarepta (SRPT) Q3 2026 Earnings Call Transcript

Sarepta's Q3 2026 revenue fell 5% year over year to $381.4 million, primarily due to lower ELEVIDYS sales, while product revenue declined 13% to $323.8 million. The company reported $22.9 million in non-GAAP operating income versus a $35.7 million loss a year earlier, and raised the low end of 2026 net product revenue guidance by $50 million to $1.25 billion–$1.30 billion. ELEVIDYS demand stabilized, but gross margin was 59%, including a 19-percentage-point impact from take-or-pay charges; management expects DM1 and FSHD multidose data in Q4 2026 and anticipates potential exon-51 competition in early 2027.

Analysis

The guidance raise is a floor-reset, not evidence of an ELEVIDYS reacceleration: enrollment-to-infusion lag means near-term sales still reflect older demand, while management itself declines to time a recovery. The key commercial tell is whether enrollment forms improve over the next two quarters; stable forms merely cap downside, they do not support a growth multiple. PMO durability cushions the franchise, but prospective exon-51 competition from Dyne makes 2027 retention and new-start data more important than this quarter’s adherence claims. Reimbursement setup may delay switching, not prevent it.

The market’s bigger source of optionality is the imminent DM1/FSHD multidose data, but management has carefully defined success around pharmacodynamic evidence, not clinical benefit. A clean knockdown/splicing package could support a rerating; weak or discordant biomarkers would expose the gap between target engagement and registrational efficacy. Novartis’s DM1 miss raises the bar on dose, patient selection, and endpoints rather than proving the mechanism is unworkable.

Reported profitability is less robust than headline operating income implies: cost reductions and prior-period comparison effects help, while take-or-pay commitments on unmade inventory reveal forecasting risk and depress product margins. Verify the charge: the article’s takeaways cite $62 million, while the transcript gives $52 million. Collaboration revenue tied partly to Roche supply should not be valued like recurring patient demand. The 2027 notes maturity is a liquidity catalyst to monitor, though current cash provides a buffer. Over 6–18 months, pivotal-study execution and regulatory decisions—not near-term reported revenue—drive the valuation.

Key Decisions for Investors

• Keep Sarepta Therapeutics at a neutral-to-underweight risk allocation before the multidose readouts; do not add on the guidance raise alone. Reassess only after full data show dose-related target knockdown plus concordant downstream biomarkers and acceptable tolerability. Falsifier: discordant biology or a dose-limiting safety signal.
• Treat the upcoming DM1/FSHD datasets as event risk, not proof of clinical efficacy. Avoid paying for an accelerated-approval outcome until the company discloses dose selection, FDA feedback, and a credible pivotal design; track these over the next 1–3 months.
• Monitor Dyne’s expected early-2027 exon-51 decision and subsequent payer access, alongside Sarepta’s new-patient starts and adherence. A restrictive competitor label or sustained Sarepta start growth would weaken the prospective-share-loss thesis; rapid payer uptake and Sarepta enrollment deterioration would strengthen it.
• Before changing exposure, reconcile the $52 million versus $62 million take-or-pay charge against the 10-Q and assess the 2027 notes maturity, cash burn, and whether Roche-related collaboration receipts recur. Treat RGNX’s potential younger-patient competition as a watch item pending regulatory clarity, not a standalone short thesis.